CD38 may be best known as a target for cancer therapies — notably J&J’s Darzalex and Sanofi’s Sarclisa. But Boehringer Ingelheim believes it has potential in immunological and fibrotic diseases, too.
The German pharma giant is acquiring a preclinical CD38 program from Ribon Therapeutics, paying an undisclosed upfront and promising future milestones.
Read the source article at endpts.com
2022-11-29 15:57:10
